Drugs / muparfostat
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00073892 | Jan 2004 → Nov 2005 | cancer of unknown primary site, cutaneous melanoma | Cellxpert Biotechnology Corp. | Completed | No outcome recorded |
| Phase 1/2 | NCT00068172 | Jul 2001 → Jun 2007 | melanoma | Cellxpert Biotechnology Corp. | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT00268593 | Aug 2005 → Feb 2008 | prostate cancer | Progen Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00130442 | Jun 2005 → Oct 2010 | melanoma | Cellxpert Biotechnology Corp. | Completed | No outcome recorded |
| Phase 2 | NCT00247728 | Jun 2004 → Jun 2008 | hepatocellular carcinoma | Cellxpert Biotechnology Corp. | Completed | No outcome recorded |
| Phase 2 | NCT00097851 | Feb 2004 → Jul 2006 | non-small cell lung carcinoma | Cellxpert Biotechnology Corp. | Completed | No outcome recorded |
| Phase 2 | NCT00103389 | Feb 2004 → May 2007 | lung cancer | Cellxpert Biotechnology Corp. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01402908 | Aug 2011 → Jul 2014 | hepatocellular carcinoma | Cellxpert Biotechnology Corp. | Terminated | No outcome recorded |
| Phase 3 | NCT00568308 | Dec 2007 → Jul 2008 | hepatocellular carcinoma | Progen Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | muparfostat | “PI-88 (muparfostat) 190 mg daily by subcutaneous injection” NCT00130442 ↗ |
| Known as | MUPARFOSTAT SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297163 ↗ |
| Known as | PI-88 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00097851 ↗ |
| Action | Inhibit | “Vascular endothelial growth factor A inhibitor” CHEMBL4297163 ↗4“Acidic fibroblast growth factor inhibitor” CHEMBL4297163 ↗ “Basic fibroblast growth factor inhibitor” CHEMBL4297163 ↗ “heparanase inhibitor PI-88” PMID 25170226 ↗ Aug 2014 “Heparanase inhibitor” CHEMBL4297163 ↗ |
| Modality | Other / unclassified | “a novel heparanase inhibitor” PMID 19303160 ↗ Feb 2009 |
| Route | Subcutaneous | “The drug will be injected subcutaneously (under the skin) once daily for 4 days every week.” NCT00068172 ↗ |
| Target | FGF1 | “Acidic fibroblast growth factor inhibitor” CHEMBL4297163 ↗ |
| Target | FGF2 | “Basic fibroblast growth factor inhibitor” CHEMBL4297163 ↗ |
| Target | HPSE | “Heparanase inhibitor” CHEMBL4297163 ↗ |
| Target | VEGFA | “Vascular endothelial growth factor A inhibitor” CHEMBL4297163 ↗ |